Merck Ph3 Trial to Evaluate Ensifentrine for AECOPD
Merck has begun patient enrollment in the ENHANCE-3 clinical trial to evaluate ensifentrine (Ohtuvayre) for preventing acute exacerbations of COPD.
Merck has begun patient enrollment in the ENHANCE-3 clinical trial to evaluate ensifentrine (Ohtuvayre) for preventing acute exacerbations of COPD.
CVS and Walgreens are expanding walk-in access, multi-vaccine scheduling, and respiratory illness testing ahead of peak viral activity.
Read MoreThe FDA approved over-the-counter Mucinex 12hr Cold & Fever Multi-Symptom.
Read MoreThe FDA approved Moderna’s mFlusiva, the first seasonal influenza vaccine using mRNA technology to enter the US market.
Read MoreMerck is seeking expand approval for its RSV drug Enflonsia to include children under age two through their second year of risk.
Read MoreA UCLA Health study compared azithromycin and roflumilast in protecting against acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Read MoreOrzeyful is the first drug to target the underlying loss of orexin signaling to address the full range of narcolepsy type 1.
Read MoreIn kidney transplant recipients, early antiviral treatment with remdesivir reduced the risk of organ rejection and heart complications by nearly half for up to one year after diagnosis.
Read MoreZidesamtinib (Jideytro) is approved for patients with ROS1-positive non-small cell lung cancer who have previously received targeted therapy.
Read MoreAstraZeneca’s triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
Read MoreWindward Bio is evaluating WIN378, a monoclonal antibody designed for twice-yearly dosing in patients with moderate-to-severe COPD.
Read MoreA large-scale study finds that the introduction of asthma biologics in 2015 has led to immediate and sustained reductions in exacerbations at the population level.
Read MoreA US study is evaluating a drug-coated balloon designed to improve outcomes for chronic rhinosinusitis patients undergoing sinus surgery.
Read MoreThe FDA will review a New Drug Application for Apnimed’s AD109, an investigational oral pill for the treatment of adults with obstructive sleep apnea with a target action date of Feb 28, 2027.
Read MoreA phase 1 study is testing the safety of a microneedle device designed to deliver peanut protein through the skin for desensitization.
Read MoreNuvaira treated the first patient treated in a clinical trial evaluating a one-time lung denervation therapy for patients with specific COPD symptoms.
Read MoreGrifols enrolled the first patient in its Phase 3 SWIFT-SC clinical trial to evaluate its subcutaneous Alpha1-Proteinase Inhibitor for the treatment of alpha1-antitrypsin (AAT) deficiency.
Read More